ALBERT

Description / Table of Contents: Introduction (Moray J Campbell & Charlotte L Bevan) -- Overview (Jason Carroll) -- Part I: Reproduction and Development -- Chapter 1. Nuclear receptors in pregnancy and outcomes: clinical perspective (Luiza Borges Manna & Catherine Williamson) -- Chapter 2. Female Reproductive Systems: hormone dependence and receptor expression (Philippa TK Saunders) -- Chapter 3. Nuclear receptors in ovarian function (Darryl Russell & Doan Thao Dinh) -- Part II: Metabolism -- Chapter 4. Nuclear receptors in energy metabolism (Alina Walth, Stephan Herzig & Maria Rohm) -- Chapter 5. Nuclear Receptors and lipid sensing (James L Thorne and Giorgia Cioccoloni) -- Part III: Central Systems -- Chapter 6. Corticosteroid receptors in Cardiac health and disease (Jessica Ivy, Gillian Gray, Megan Holmes, Martin Denvir, Karen Chapman) -- Chapter 7. Physiological convergence and antagonism between GR and PPARγ in inflammation and metabolism (Marija Dacic, Gayathri Shibu and Inez Rogatsky) -- Chapter 8. Circadian Rhythm and Nuclear Receptors (David W Ray) -- Chapter 9. Vitamin D and gut health (James C Fleet) -- Part IV: Cancer -- Chapter 10. Estrogen Receptor alpha and ESR1 Mutations in Breast Cancer (Jaymin Patel & Rinath Jeselsohn) -- Chapter 11. AR structural variants and prostate cancer (Laura Cato) -- Chapter 12. ERβ and inflammation (Linnea Hases, Amena Archer & Cecilia Williams) -- Chapter 13. Genomic insights into non-steroidal nuclear receptors in prostate and breast cancer (Sajad A Wani & Moray Campbell) -- Part V: New developments in transcriptional control by nuclear receptors -- Chapter 14. Protein condensation in the nuclear receptor family; implications for transcriptional output (Monique Appelman, Elle Hollaar, Jurian Schuijers & Saskia WC van Mil) -- Chapter 15. Prostate cancer epigenetic plasticity and enhancer heterogeneity: molecular causes, consequences and clinical implications (Jeroen Kneppers, Andries M Bergman & Wilbert Zwart) -- Chapter 16. Epigenetic coregulation of androgen receptor signaling (Rayzel Fernandes, Damien A. Leach & Charlotte Bevan) -- Part VI: Clinical Translation -- Chapter 17. Cllnical Translation: Targeting the Estrogen Receptor (Jennifer O. Lauchle & Ciara Metcalfe) -- Chapter 18. Drugging the undruggable: targeting the N-terminal domain of nuclear hormone receptors (Marianne Sadar) -- Chapter 19. Genetic Variation and Mendelian Randomization approaches (Mojgan Yazdanpanah, Nahid Yazdanpanah & Despoina Manousaki) -- Index.

Description / Table of Contents: Foreword -- Preface -- Chapter 1. The Year 1975 -- Chapter 2. The Effects of the Social and Behavioral Sciences -- Chapter 3. Little Biology and Biology of the Little -- Chapter 4. The Big End of the Spectrum -- Chapter 5. A Second “Time of Tumult” and A New Home for Biology -- Chapter 6. Technology and the “Fearless Biologists” -- Chapter 7. Genes and Beyond -- Chapter 8. Integrating Biology -- Chapter 9. Expanding Big Bio -- Epilogue -- Index.

Description / Table of Contents: Preface -- Section I Cluster and Classification Models -- Hierarchical Clustering and K-means Clustering to Identify Subgroups in Surveys (50 Patients) -- Density-based Clustering to Identify Outlier Groups in Otherwise Homogeneous Data (50 Patients) -- Two Step Clustering to Identify Subgroups and Predict Subgroup Memberships in Individual Future Patients (120 Patients) -- Nearest Neighbors for Classifying New Medicines (2 New and 25 Old Opioids) -- Predicting High-Risk-Bin Memberships (1445 Families) -- Predicting Outlier Memberships (2000 Patients) -- Data Mining for Visualization of Health Processes (150 Patients) -- Trained Decision Trees for a More Meaningful Accuracy (150 Patients) -- Typology of Medical Data (51 Patients) -- Predictions from Nominal Clinical Data (450 Patients) -- Predictions from Ordinal Clinical Data (450 Patients) -- Assessing Relative Health Risks (3000 Subjects) -- Measurement Agreements (30 Patients) -- Column Proportions for Testing Differences between Outcome Scores (450 Patients) -- Pivoting Trays and Tables for Improved Analysis of Multidimensional Data (450 Patients) -- Online Analytical Procedure Cubes for a More Rapid Approach to Analyzing Frequencies (450 Patients) -- Restructure Data Wizard for Data Classified the Wrong Way (20 Patients) -- Control Charts for Quality Control of Medicines (164 Tablet Desintegration Times) -- Section II (Log) Linear Models -- Linear, Logistic, and Cox Regression for Outcome Prediction with Unpaired Data (20, 55, and 60 Patients) -- Generalized Linear Models for Outcome Prediction with Paired Data (100 Patients and 139 Physicians) -- Generalized Linear Models for Predicting Event-Rates (50 Patients) -- Factor Analysis and Partial Least Squares (PLS) for Complex-Data Reduction (250 Patients) -- Optimal Scaling of High-sensitivity Analysis of Health Predictors (250 Patients) -- Discriminant Analysis for Making a Diagnosis from Multiple Outcomes (45 Patients) -- Weighted Least Squares for Adjusting Efficacy Data with Inconsistent Spread (78 Patients) -- Partial Correlations for Removing Interaction Effects from Efficacy Data (64 Patients) -- Canonical Regression for Overall Statistics of Multivariate Data (250 Patients) -- Multinomial Regression for Outcome Categories (55 Patients) -- Various Methods for Analyzing Predictor Categories (60 and 30 Patients) -- Random Intercept Models for Both Outcome and Predictor Categories (55 Patients) -- Automatic Regression for Maximizing Linear Relationships (55 Patients) -- Simulation Models for Varying Predictors (9000 Patients) -- Generalized Linear Mixed Models for Outcome Prediction from Mixed Data (20 Patients) -- Two Stage Least Squares for Linear Models with Problematic Predictors (35 Patients) -- Autoregressive Models for Longitudinal Data (120 Monthly Population Records) -- Variance Components for Assessing the Magnitude of Random Effects (40 Patients) -- Ordinal Scaling for Clinical Scores with Inconsistent Intervals (900 Patients) -- Loglinear Models for Assessing Incident Rates with Varying Incident Risks (12 Populations) -- Loglinear Models for Outcome Categories (445 Patients) -- More on Polytomous Outcome Regressions (450 Patients) -- Heterogeneity in Clinical Research: Mechanisms Responsible (20 Studies) -- Performance Evaluation of Novel Diagnostic Tests (650 and 588 Patients) -- Quantile - Quantile Plots, a Good Start for Looking at Your Medical Data (50 Cholesterol Measurements and 52 Patients) -- Rate Analysis of Medical Data Better than Risk Analysis (52 Patients) -- Trend Tests Will Be Statistically Significant if Traditional Tests Are not (30 and 106 Patients) -- Doubly Multivariate Analysis of Variance for Multiple Observations from Multiple Outcome Variables (16 Patients) -- Probit Models for Estimating Effective Pharmacological Treatment Dosages (14 Tests) -- Interval Censored Data Analysis for Assessing Mean Time to Cancer Relapse (51 Patients) -- Structural Equation Modeling with SPSS Analysis of Moment Structures (Amos) for Cause Effect Relationships I (35 Patients) -- Structural Equation Modeling with SPSS Analysis of Moment Structures (Amos) for Cause Effect Relationships II (35 Patients) -- Firth's Bias-adjusted Estimates for Biased Logistic Data Models (23 Challenger launchings) -- Omics Research (125 Patients, 24 Predictor Variables) -- Sparse Canonical Correlation Analysis (12209 Genes in 45 Glioblastoma Carriers) -- Eigenvalues, Eigenvectors and Eigenfunctions (45 and 250 Patients) -- Section III Rules Models -- Neural Networks for Assessing Relationships that are Typically Nonlinear (90 Patients) -- Complex Samples Methodologies for Unbiased Sampling (9,678 Persons) -- Correspondence Analysis for Identifying the Best of Multiple Treatments in Multiple Groups (217 Patients) -- Decision Trees for Decision Analysis (1004 and 953 Patients) -- Multidimensional Scaling for Visualizing Experienced Drug Efficacies (14 Pain-killers and 42 Patients) -- Stochastic Processes for Long Term Predictions from Short Term Observations -- Optimal Binning for Finding High Risk Cut-offs (1445 Families) -- Conjoint Analysis for Determining the Most Appreciated Properties of Medicines to Be Developed (15 Physicians) -- Item Response Modeling for Analyzing Quality of Life with Better Precision (1000 Patients) -- Survival Studies with Varying Risks of Dying (50 and 60 Patients) -- Fuzzy Logic for Improved Precision of Pharmacological Data Analysis (9 Induction Dosages) -- Automatic Data Mining for the Best Treatment of a Disease (90 Patients) -- Pareto Charts for Identifying the Main Factors of Multifactorial Outcomes (2000 Admissions to Hospital) -- Radial Basis Neural Networks for Multidimensional Gaussian Data (90 persons) -- Automatic Modeling for Drug Efficacy Prediction (250 Patients) -- Automatic Modeling for Clinical Event Prediction (200 Patients) -- Automatic Newton Modeling in Clinical Pharmacology (15 Alfentanil dosages, 15 Quinidine time-concentration relationships) -- Spectral Plots for High Sensitivity Assessment of Periodicity (6 Years’ Monthly C Reactive Protein Levels) -- Runs Test for Identifying Best Analysis Models (21 Estimates of Quantity and Quality of Patient Care) -- Evolutionary Operations for Health Process Improvement (8 Operation Room Settings) -- Bayesian Networks for Cause Effect Modeling (600 Patients) -- Support Vector Machines for Imperfect Nonlinear Data (200 Patients) -- Multiple Response Sets for Visualizing Clinical Data Trends (811 Patient Visits) -- Protein and DNA Sequence Mining -- Iteration Methods for Crossvalidation (150 Patients) -- Testing Parallel-groups with Different Sample Sizes and Variances (5 Parallel-group Studies) -- Association Rules between Exposure and Outcome (50 and 60 Patients) -- Confidence Intervals for Proportions and Differences in Proportions (100 and 75 Patients) -- Ratio Statistics for Efficacy Analysis of New Drugs 50 Patients) -- Fifth Order Polynomes of Circadian Rhythms (1 Patient) -- Gamma Distribution for Estimating the Predictors of Medical Outcomes (110 Patients) -- Index.

Description / Table of Contents: Chapter 1: Introduction: a decade teaching stem cell biology -- Chapter 2: Preimplantation development: from germ cells to blastocyst -- Chapter 3: Origins of pluripotency: from stem cells to germ cells -- Chapter 4: Human induced pluripotent stem (hiPS) cells: generation and applications -- Chapter 5: Cellular reprogramming and aging -- Chapter 6: Cloning -- Chapter 7: Stem cells in plant development -- Chapter 8: Axial stem cells and the formation of the vertebrate body -- Chapter 9: Skeletal muscle development - from stem cells to body movement -- Chapter 10: Cardiac regeneration and repair: from mechanisms to therapeutic strategies -- Chapter 11: Reproducing human brain development in vitro: generating cerebellar neurons for modelling cerebellar ataxias -- Chapter 12: Neurotoxicology and disease modelling -- Chapter 13: Mesenchymal stem cells for cutaneous wound healing.

Description / Table of Contents: Microfluidic devices and three dimensional-printing strategies for in vitro models of bone -- Microfluidics for Processing of biomaterials -- Organ-on-a-chip -- Body-on-a-chip: Current challenges -- Biomaterials and microfluidics for liver models -- Microfluidics for CNS research -- Biomaterials and microfluidics for angiogenesis research -- Biomaterials and microfluidics for drug discovery and development -- Microfluidics for diagnostics -- Nanoparticles and Microfluidic devices in cancer research.

Description / Table of Contents: Foreword -- Cardiac mechanoperception and mechanotransduction - Mechanisms of stretch sensing in cardiomyocytes and implications for cardiomyopathy -- Mechanotransduction in heart development -- Mechanobiology of cardiac growth in health and disease -- The role of mechanosensitive signaling cascades in repair and fibrotic remodeling of the infarcted heart -- Mechanobiology of cardiac fibroblasts in cardiac remodelling -- Mechanobiology of cardiac remodelling in cardiomyopathy -- Biophysical Stretch Induced Differentiation and Maturation of Induced Pluripotent Stem Cell-derived Cardiomyocytes -- Mechanical Considerations of Myocardial Tissue and Cardiac Regeneration -- Mechanobiology of Exercise-Induced Cardiac Remodeling in Health and Disease -- Cardiac microvascular endothelial cells and pressure overload-induced cardiac fibrosis -- Cellular and Subcellular Mechanisms of Ventricular Mechano-Arrhythmogenesis -- Computational biomechanics of ventricular dyssynchrony and resynchronization therapy -- Therapeutic innovations for heart failure.

Description / Table of Contents: Part I: Defining The Problem -- Chapter 1: Introduction -- Chapter 2: Challenging Perceptions - What is mental health anyway? -- Chapter 3: Setting the Scene - Understanding the PhD Mental Health Crisis -- Part II: Mindset Matters -- Chapter 4: Self-Care: Without you there is no PhD -- Chapter 5: Not another yoga session - University Wellbeing programs and why they so often miss the mark -- Chapter 6: “I’ll read it later” and other lies we tell ourselves – Managing Expectations and Guilt -- Chapter 7: Why you earned it – Fighting the Impostor -- Part III: Environmental Stressors -- Chapter 8: Dismantling the Ivory Tower – Systemic Issues that Might Impact your Mental Health -- Chapter 9: Perhaps it’s not you it’s them: PhD Student-Supervisor relationships -- Chapter 10: Publish or Perish – On the Myth of Meritocracy -- Chapter 11: The High-Walled Rose Garden: Understanding there is life outside the academy -- Part IV: Seeking Help -- Chapter 12: Thriving, not just surviving.

Description / Table of Contents: Dedication -- About the editors -- Preface (Jarvis JUM) -- Chapter 1. Social evolution in African mole-rats - a comparative overview (Faulkes CG & Bennett NC) -- Chapter 2. Social behavior in naked mole-rats: individual differences in phenotype and proximate mechanisms of mammalian eusociality (Holmes MM & Goldman BD) -- Chapter 3. Neuropeptidergic and neuroendocrine systems underlying eusociality and the concomitant social regulation of reproduction in naked mole-rats: a comparative approach (Coen CW, Bennett N, Holmes MM, & Faulkes CG) -- Chapter 4. Adult neural plasticity in naked mole-rats: implications of fossoriality, longevity and sociality on the brain’s capacity for change (Mooney SJ, Forger NG, & Holmes MM) -- Chapter 5. Sensory Systems of the African Naked Mole-Rat (Vice EN, Lagestee S, Browe BM, Deb D, Smith ESJ, Park TJ) -- Chapter 6. Hearing and vocalizations in the naked mole-rat (Barker AJ, Koch, U, Lewin GR, Pyott, SJ) -- Chapter 7. The somatosensory world of the African naked mole-rat (Lewin GR, Smith ESJ, Reznick J, Debus K, Barker A, and Park TJ) -- Chapter 8. The idiosyncratic physiological traits of the naked mole-rat; a resilient animal model of aging, longevity, and healthspan (Buffenstein R and Craft W) -- Chapter 9. African Naked Mole-Rats Demonstrate Extreme Tolerance to Hypoxia and Hypercapnia (Park TJ, Smith ESJ, Reznick J, Bennett NC, Applegate DT, Larson J, Lewin GR) -- Chapter 10. A sweet story of metabolic innovation in the naked mole-rat (Reznick J, Park TJ, and Lewin GR) -- Chapter 11. Insights into the molecular basis of genome stability and pristine proteostasis in naked mole-rats (Narayan V, McMahon M, O’Brien J, McAllister F and Buffenstein R) -- Chapter 12. The Unusual Immune System of the Naked Mole-Rat (Lin TD and Buffenstein R) -- Chapter 13 -- Induced Pluripotent Stem Cells from Cancer-Resistant Naked Mole-rats (Miura. K, Oiwa Y, and Kawamura Y) -- Chapter 14. Naked mole-rats: resistant to developing cancer or good at avoiding it? (Hadi F, Smith ESJ and Khaled WT) -- Chapter 15. Spontaneous Disease and Pathology of Naked Mole-rats (Delaney MA, Imai DM, Buffenstein R) -- Chapter 16. Managed Care of Naked Mole-rats (Smith M, and Buffenstein¬ R) -- Chapter 17. Some exciting future directions for work on naked mole-rats (Smith ESJ, ParkTJ, Holmes MM and Buffenstein R).